ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes financial report for the period of January – March 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.
CEO Dr. Steen Klysner comments
“The Company’s revenues in the first quarter of 2019 were 19 % above the result from Q1 in the same period last year. It is also notably 90 % higher than the 2018 Q4 result, which we consider to be a sign of the emerging impact from the platform investments in combination with the